Francesco Summaria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francesco Summaria has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Enrico Romagnoli
Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
27 shared publications Roberto Patrizi
19 shared publicationsErnesto Lioy
Interventional Cardiology Policlinico Casilino Rome Italy
17 shared publicationsMarina Mustilli
CCU S. Pertini Hospital
11 shared publications- Alessandro Sciahbasi
Interventional Cardiology, Sandro Pertini Hospital—ASL RM2, 00157 Rome, Italy
9 shared publications - Carlo Trani
Catholic University of the Sacred Heart
9 shared publications
Latest Publications
- Open Access
- 7 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (22) , 6956
New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events
Patients with an established diagnosis of heart failure (HF) with reduced ejection fraction (HFrEF) are prone to experience episodes of worsening symptoms and signs despite continued therapy, termed “worsening heart failure” (WHF). Despite guideline-directed medical therapy, worsening of chronic heart failure accounts for almost 50% of all hospital admissions for HF, and patients experiencing WHF carry a substantially higher risk of death and hospitalization than patients with “stable” HF. New drugs are emerging as arrows in the quiver for clinicians to address the residual risk of HF hospitalization and cardiovascular deaths in patients with WHF. This question-and-answer-based review will discuss the emerging definition of WHF in light of the recent clinical consensus released by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), the new therapeutic approaches to treat WHF and then move on to their timing and safety concerns (i.e., renal profile).
- 7 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (22) , 6956
Open AccessNew Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events
Patients with an established diagnosis of heart failure (HF) with reduced ejection fraction (HFrEF) are prone to experience episodes of worsening symptoms and signs despite continued therapy, termed “worsening heart failure” (WHF). Despite guideline-directed medical therapy, worsening of chronic heart failure accounts for almost 50% of all hospital admissions for HF, and patients experiencing WHF carry a substantially higher risk of death and hospitalization than patients with “stable” HF. New drugs are emerging as arrows in the quiver for clinicians to address the residual risk of HF hospitalization and cardiovascular deaths in patients with WHF. This question-and-answer-based review will discuss the emerging definition of WHF in light of the recent clinical consensus released by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), the new therapeutic approaches to treat WHF and then move on to their timing and safety concerns (i.e., renal profile).
- 1 July 2023
- Published by Edizioni Minerva Medica in Minerva Cardiology and Angiology
- Vol. 71 (4) , 363-373
Dual pathway inhibition in atherothrombosis prevention: yes, now we can!
Article: Dual pathway inhibition in atherothrombosis prevention: yes, now we can! - Minerva Cardiology and Angiology 2021 Nov 11 - Minerva Medica - Journals
- 1 July 2023
- Published by Edizioni Minerva Medica in Minerva Cardiology and Angiology
- Vol. 71 (4) , 363-373
Dual pathway inhibition in atherothrombosis prevention: yes, now we can!
Article: Dual pathway inhibition in atherothrombosis prevention: yes, now we can! - Minerva Cardiology and Angiology 2021 Nov 11 - Minerva Medica - Journals
- Open Access
- 4 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3207
Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network
Background: Direct oral anticoagulants (DOACs) are the preferred anticoagulant drugs for the prevention of atrial fibrillation (AF)-related thromboembolic complications and for the treatment and the prevention of recurrences of venous thromboembolism (VTE). The evaluation of self-reported adverse drug reactions (ADRs) available from databases of drug-regulatory agencies such as the Italian Medicines Agency (AIFA) pharmacovigilance database represents a novel aid to guide decision making. Objective: To assess the safety profile of DOACs by analyzing ADR rates in the real-world Italian scenario. Methods: Post-marketing surveillance data recorded by the National Pharmacovigilance Network were retrieved for the time period 2017–2021 from the AIFA online site. The following data were collected for each DOAC: total ADR number, serious ADR number, gastrointestinal (GI) ADR, intracranial hemorrhage events (ICH ADR), and more frequently reported ADR for the study year. The safety profile was expressed by the risk index (RI). Results: Rivaroxaban use was associated with consistent and stable low rates of serious ADR, GI ADR, and ICH ADR across the 5-year study period. Rivaroxaban and apixaban showed the lowest RI for serious ADR and GI ADR, while rivaroxaban use was associated with significantly lower ICH events as compared to apixaban. Dabigatran was related to the highest RIs for every ADR class, in particular GI ADRs. Conclusions: DOACs presented an acceptable safety profile in the current post-market analysis. However, rivaroxaban and apixaban were associated with more favorable safety profiles as compared to dabigatran, while rivaroxaban provoked statistically significantly fewer ICH events as compared to apixaban.
- 4 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3207
Open AccessFive Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network
Background: Direct oral anticoagulants (DOACs) are the preferred anticoagulant drugs for the prevention of atrial fibrillation (AF)-related thromboembolic complications and for the treatment and the prevention of recurrences of venous thromboembolism (VTE). The evaluation of self-reported adverse drug reactions (ADRs) available from databases of drug-regulatory agencies such as the Italian Medicines Agency (AIFA) pharmacovigilance database represents a novel aid to guide decision making. Objective: To assess the safety profile of DOACs by analyzing ADR rates in the real-world Italian scenario. Methods: Post-marketing surveillance data recorded by the National Pharmacovigilance Network were retrieved for the time period 2017–2021 from the AIFA online site. The following data were collected for each DOAC: total ADR number, serious ADR number, gastrointestinal (GI) ADR, intracranial hemorrhage events (ICH ADR), and more frequently reported ADR for the study year. The safety profile was expressed by the risk index (RI). Results: Rivaroxaban use was associated with consistent and stable low rates of serious ADR, GI ADR, and ICH ADR across the 5-year study period. Rivaroxaban and apixaban showed the lowest RI for serious ADR and GI ADR, while rivaroxaban use was associated with significantly lower ICH events as compared to apixaban. Dabigatran was related to the highest RIs for every ADR class, in particular GI ADRs. Conclusions: DOACs presented an acceptable safety profile in the current post-market analysis. However, rivaroxaban and apixaban were associated with more favorable safety profiles as compared to dabigatran, while rivaroxaban provoked statistically significantly fewer ICH events as compared to apixaban.
- 1 December 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 345, 90-97
New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation
- 1 December 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 345, 90-97
New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation
- Open Access
- 5 March 2018
- Published by Wiley in Case Reports in Cardiology
- Vol. 2018, 1-5
Safety and Efficacy of Triple Therapeutic Targets with Rivaroxaban after Acute Myocardial Infarction Complicated by Left Ventricular Thrombi in a Case of Nonvalvular Atrial Fibrillation
We present the complex case of a high-risk patient with nonvalvular atrial fibrillation, who experienced a non-ST elevation myocardial infarction complicated by left ventricular (LV) thrombi and underwent percutaneous coronary intervention with drug-eluting stent implantation. The patient was initially treated with short-term triple therapy including aspirin, clopidogrel, and rivaroxaban 15 mg/die. Following aspirin dropping one month after discharge, the patient continued on dual therapy with clopidogrel and rivaroxaban, and a clinical and imaging follow-up at 6 and 12 months confirmed the LV thrombi resolution, with no thromboembolic episodes and a good safety profile.
- 5 March 2018
- Published by Wiley in Case Reports in Cardiology
- Vol. 2018, 1-5
Open AccessSafety and Efficacy of Triple Therapeutic Targets with Rivaroxaban after Acute Myocardial Infarction Complicated by Left Ventricular Thrombi in a Case of Nonvalvular Atrial Fibrillation
We present the complex case of a high-risk patient with nonvalvular atrial fibrillation, who experienced a non-ST elevation myocardial infarction complicated by left ventricular (LV) thrombi and underwent percutaneous coronary intervention with drug-eluting stent implantation. The patient was initially treated with short-term triple therapy including aspirin, clopidogrel, and rivaroxaban 15 mg/die. Following aspirin dropping one month after discharge, the patient continued on dual therapy with clopidogrel and rivaroxaban, and a clinical and imaging follow-up at 6 and 12 months confirmed the LV thrombi resolution, with no thromboembolic episodes and a good safety profile.
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 18 (10) , 796-797
Arrhythmogenic right-ventricular cardiomyopathy and cardiac microvascular disease
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 18 (10) , 796-797
Arrhythmogenic right-ventricular cardiomyopathy and cardiac microvascular disease
- 2 August 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 91 (5) , 851-858
Angiographic and clinical performance of polymer‐free biolimus‐eluting stent in patients with ST‐segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study
Objectives: This study aimed at assessing the performance of a new generation polymer‐free biolimus‐eluting stent (BES) in real‐world patients with ST‐segment elevation myocardial infarction (STEMI).Background: Polymers components of early‐generation drug‐eluting stents have been implicated in the pathogenesis of delayed arterial healing, vessel remodeling, and delayed stent thrombosis. Recently, a novel polymer‐free BES has shown excellent clinical performance in clinical trial setting.Methods: Overall, 175 consecutive patients (64 ± 14 years, 141 men) treated with the BioFreedom (Biosensors Europe, Morges, Switzerland) polymer‐free BES because of STEMI were included in this study. The primary endpoint was the rate of major adverse cardiac events (MACE), a composite of cardiac death, recurrent myocardial infarction, and ischemia‐driven target vessel revascularization at 1 year follow‐up. A subgroup of patients underwent 6‐month angiographic follow‐up. Dual antiplatelet therapy was prescribed for 12 months after STEMI.Results: At 1 year, the cumulative rate of MACE was 4.6%. One patient (0.6%) had an arrhythmic cardiac death and five (2.9%) had ischemia‐driven target vessel revascularization, although only three (1.7%) had target lesion revascularization. Two (1.1%) patients had acute stent thrombosis yielding nonfatal myocardial infarction. In 70 patients (63 ± 14 years, 61 men), quantitative coronary angiography at 6‐month follow‐up revealed diameter stenosis of 24.1 ± 13.7% and minimal lumen diameter of 2.29 ± 0.56 mm, yielding a late lumen loss of 0.13 ± 0.14 mm.Conclusions: In real‐world setting, implantation of a new‐generation polymer‐free BES during STEMI is associated with favorable clinical and angiographic results, pointing toward the overall efficacy and safety of the device in complex clinical scenarios.
- 2 August 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 91 (5) , 851-858
Angiographic and clinical performance of polymer‐free biolimus‐eluting stent in patients with ST‐segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study
Objectives: This study aimed at assessing the performance of a new generation polymer‐free biolimus‐eluting stent (BES) in real‐world patients with ST‐segment elevation myocardial infarction (STEMI).Background: Polymers components of early‐generation drug‐eluting stents have been implicated in the pathogenesis of delayed arterial healing, vessel remodeling, and delayed stent thrombosis. Recently, a novel polymer‐free BES has shown excellent clinical performance in clinical trial setting.Methods: Overall, 175 consecutive patients (64 ± 14 years, 141 men) treated with the BioFreedom (Biosensors Europe, Morges, Switzerland) polymer‐free BES because of STEMI were included in this study. The primary endpoint was the rate of major adverse cardiac events (MACE), a composite of cardiac death, recurrent myocardial infarction, and ischemia‐driven target vessel revascularization at 1 year follow‐up. A subgroup of patients underwent 6‐month angiographic follow‐up. Dual antiplatelet therapy was prescribed for 12 months after STEMI.Results: At 1 year, the cumulative rate of MACE was 4.6%. One patient (0.6%) had an arrhythmic cardiac death and five (2.9%) had ischemia‐driven target vessel revascularization, although only three (1.7%) had target lesion revascularization. Two (1.1%) patients had acute stent thrombosis yielding nonfatal myocardial infarction. In 70 patients (63 ± 14 years, 61 men), quantitative coronary angiography at 6‐month follow‐up revealed diameter stenosis of 24.1 ± 13.7% and minimal lumen diameter of 2.29 ± 0.56 mm, yielding a late lumen loss of 0.13 ± 0.14 mm.Conclusions: In real‐world setting, implantation of a new‐generation polymer‐free BES during STEMI is associated with favorable clinical and angiographic results, pointing toward the overall efficacy and safety of the device in complex clinical scenarios.
- 1 May 2017
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 18 (5) , 291-294
Cocaine and coronary artery diseases
Cocaine is associated with important cardiac complications such as sudden death, acute myocarditis, dilated cardiomyopathy, life-threatening arrhythmias, and myocardial ischemia as well as infarction. It is well known that cocaine may induce vasospasm through adrenergic stimulation of the coronary arteries. Moreover, cocaine may promote intracoronary thrombosis, triggered by alterations in the plasma constituents, and platelet aggregation, leading to subsequent myocardial infarction. The long-term use of cocaine may stimulate atherosclerosis, probably through endothelial cell dysfunction. Significant and severe coronary atherosclerosis is common in young chronic cocaine users and there is probably a relationship between the duration and frequency of cocaine use and the extent of coronary disease.
- 1 May 2017
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 18 (5) , 291-294
Cocaine and coronary artery diseases
Cocaine is associated with important cardiac complications such as sudden death, acute myocarditis, dilated cardiomyopathy, life-threatening arrhythmias, and myocardial ischemia as well as infarction. It is well known that cocaine may induce vasospasm through adrenergic stimulation of the coronary arteries. Moreover, cocaine may promote intracoronary thrombosis, triggered by alterations in the plasma constituents, and platelet aggregation, leading to subsequent myocardial infarction. The long-term use of cocaine may stimulate atherosclerosis, probably through endothelial cell dysfunction. Significant and severe coronary atherosclerosis is common in young chronic cocaine users and there is probably a relationship between the duration and frequency of cocaine use and the extent of coronary disease.
- 1 November 2016
- Published by Il Pensiero Scientifico Editore in Giornale Italiano di Cardiologia
- Vol. 17 (11) , 873-880
Lo studio ABSORB III
- 1 November 2016
- Published by Il Pensiero Scientifico Editore in Giornale Italiano di Cardiologia
- Vol. 17 (11) , 873-880
Lo studio ABSORB III